Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study.
Clare BaileyUsha ChakravarthyAndrew John LoteryGeeta MenonJames Stephen Talksnull nullPublished in: Eye (London, England) (2021)
The FAc implant was well tolerated, with predictable and manageable IOP-related events while delivering a continuous microdose of corticosteroid to eyes with cDMO, providing prolonged vision preservation and a reduced number of treatments.